**Background**
Cancer remains one of the most challenging health crises globally, characterized by uncontrolled cell proliferation and the evasion of apoptosis. Many malignancies are driven by the aberrant activation of receptor tyrosine kinases, which trigger downstream signaling pathways that promote tumor growth, survival, and angiogenesis. Among these, Fms-like tyrosine kinase 3 (FLT3) and Vascular Endothelial Growth Factor Receptors (VEGFRs) are critical drivers in various hematologic and solid tumors. Specifically, mutations in FLT3 are frequently associated with aggressive forms of leukemia, making the inhibition of both wild-type and mutated forms of these kinases a primary goal in oncology. In this context, we will introduce a potent multikinase inhibitor – 4SC-203.
**Definition**
4SC-203 is a potent multikinase inhibitor with potential antineoplastic activity. According to the 4SC-203 description, this compound selectively targets FLT3/STK1, mutated forms of FLT3, and VEGFRs.
**Mechanism of Action**
The 4SC-203 biological activity is characterized by its ability to block the phosphorylation and activation of multiple kinase targets. By inhibiting FLT3, it disrupts the signaling essential for the proliferation of leukemic blasts. Simultaneously, its activity against VEGFRs allows it to interfere with the angiogenic process, thereby restricting the blood supply to the tumor microenvironment. The 4SC-203 Formula is C33H38N8O4S, with a molecular weight of 642.77, providing the structural basis for its high affinity toward these specific kinase domains.
**Experimental Studies**
Research into 4SC-203 in vitro has demonstrated its efficacy as a multikinase inhibitor capable of suppressing the growth of cancer cells by targeting key survival pathways. By selectively inhibiting FLT3 and its mutated variants, the compound exhibits significant antineoplastic potential. While specific IC50 values and animal model dosages are detailed in the 4SC-203 Data Sheet, the overall profile indicates a strong capacity for inhibiting tumor progression. In conclusion, 4SC-203 is a potent multikinase inhibitor that holds promise for the treatment of cancers driven by FLT3 and VEGFR signaling.
Keywords
4SC-203, 895533-09-2, FLT3, VEGFR, Cluster of differentiation antigen 135, CD135, Fms like tyrosine kinase 3, Vascular endothelial growth factor receptor, multikinase, antineoplastic, FLT3/STK1, tumor, Inhibitor, inhibitor, inhibit
References
[1] A multikinase inhibitor with potential antineoplastic activity. Multikinase inhibitor